Mineralys Therapeutics (MLYS) Shares Outstanding (Weighted Average) (2022 - 2026)
Quarterly results put Shares Outstanding (Weighted Average) at $82.8 million for Q1 2026, up 55.81% from a year ago — trailing twelve months through Mar 2026 was $82.8 million (up 55.81% YoY), and the annual figure for FY2025 was $67.7 million, up 39.38%.
Mineralys Therapeutics has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $82.8 million for Q1 2026.
- Shares Outstanding (Weighted Average) reached $82.8 million in Q1 2026 per MLYS's latest filing, up from $67.7 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $82.8 million in Q1 2026 and bottomed at $5.1 million in Q1 2022.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $44.9 million (2024), compared with a mean of $39.8 million.
- The largest annual shift saw Shares Outstanding (Weighted Average) surged 600.33% in 2023 before it increased 18.4% in 2025.
- Over 5 years, Shares Outstanding (Weighted Average) stood at $5.2 million in 2022, then soared by 600.33% to $36.2 million in 2023, then soared by 34.13% to $48.5 million in 2024, then skyrocketed by 39.38% to $67.7 million in 2025, then grew by 22.43% to $82.8 million in 2026.
- Business Quant data shows Shares Outstanding (Weighted Average) for MLYS at $82.8 million in Q1 2026, $67.7 million in Q4 2025, and $70.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 104.00 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 16.04 Bn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | 82.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.83 Mn |
| Dec 31, 2025 | 67.66 Mn |
| Sep 30, 2025 | 70.59 Mn |
| Jun 30, 2025 | 65.45 Mn |
| Mar 31, 2025 | 53.16 Mn |
| Dec 31, 2024 | 48.54 Mn |
| Sep 30, 2024 | 48.06 Mn |
| Jun 30, 2024 | 47.18 Mn |
| Mar 31, 2024 | 44.90 Mn |
| Dec 31, 2023 | 36.19 Mn |
| Sep 30, 2023 | 34.87 Mn |
| Jun 30, 2023 | 32.30 Mn |
| Mar 31, 2023 | 24.76 Mn |
| Dec 31, 2022 | 5.17 Mn |
| Sep 30, 2022 | 5.18 Mn |
| Jun 30, 2022 | 5.14 Mn |
| Mar 31, 2022 | 5.12 Mn |